Articles
Putting the Patient First: Not Just When It’s Convenient
Introduction
Successful clinical trials rely on effective patient recruitment and retention. However, a 2019 report indicates that the industry continues to struggle meeting these objectives. The study found that about 80 percent of clinical trials don’t meet patient enrollment deadlines,...
Clinical Trials
CluePoints Central Statistical Monitoring Supports Business Continuity as Coronavirus Impacts Clinical Trial Operations
CluePoints, the premier provider of Risk-Based Trial Execution (RBx) and Data Quality Oversight Software for clinical trials, announced that it has seen a dramatic increase in demand for remote and centralized site monitoring amid the ongoing Coronavirus outbreak. With...
Clinical Trials
Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement
Zydus Cadila, an innovation-driven global pharmaceutical company, and XOMA Corporation announced they have entered into a licensing agreement to advance an IL-2-based immuno-oncology (IO) drug candidate that combines Zydus’ IL-2 with XOMA’s novel anti-IL-2 monoclonal antibody.
As part of the...
Clinical Trials
Clinerion received ISO 27001:2013 certification
Clinerion has gained ISO 27001:2013 certification, the international standard that describes best practice for an information security management system (ISMS).
ISO 27001:2013 is a standard set by the International Organization for Standardization (ISO), the independent, non-governmental international organization of national...
Articles
The unexpected benefits of clinical trial disclosure
Introduction:
Patients, clinical trial sponsors and institutions are starting to benefit from increased transparency commitments and significant investments in trial data disclosure. To make an ever-broader scope of trial data public, leading pharmaceutical organizations have been refining their processes and...
Clinical Trials
Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension
Bellerophon Therapeutics, Inc , a clinical-stage biotherapeutics company, announced the successful completion of its End-of-Phase 2 Meetings with the U.S. FDA for INOpulse for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF).
The Company, in consultation with the...
Clinical Trials
Clinerion and iClusion partner to boost the identification and recruitment of more patients into clinical trials
Clinerion’s Patient Network Explorer and iClusion’s Trial Eye platforms both connect clinical trial sponsors with networks of partner hospitals, giving trial managers the ability to include eligible patients for trials more quickly and efficiently than before. Treating physicians and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read